Kura Oncology shares long-term FIT-001 data on darlifarnib-cabozantinib combo in advanced kidney cancer at KCRS 2026 - KURA News | RalliesKura Oncology shares long-term FIT-001 data on darlifarnib-cabozantinib combo in advanced kidney cancer at KCRS 2026
K
KURA• FIT-001 data to be presented at Kidney Cancer Research Summit
- Kura Oncology flagged updated long-term Phase 1a data for darlifarnib with cabozantinib in advanced clear cell renal cell carcinoma.
- Results from the FIT-001 study will be presented in an oral session at the Kidney Cancer Research Summit on July 24, 2026.
- A randomized Phase 1b trial comparing the combination versus cabozantinib alone is enrolling in the U.S. and EU.
- Management plans a virtual investor call on July 27, 2026 to discuss the RCC program.
XLE
•
